Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 5
1981 3
1982 8
1983 3
1984 10
1985 17
1986 18
1987 14
1988 11
1989 18
1990 13
1991 3
1992 15
1993 19
1994 9
1995 17
1996 13
1997 30
1998 24
1999 22
2000 43
2001 65
2002 76
2003 109
2004 113
2005 143
2006 165
2007 176
2008 154
2009 219
2010 200
2011 223
2012 293
2013 260
2014 271
2015 230
2016 187
2017 203
2018 155
2019 128
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

3,304 results
Results by year
Filters applied: . Clear all
Page 1
Venetoclax with decitabine or azacitidine for AML.
Das M. Das M. Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1. Lancet Oncol. 2018. PMID: 30392809 No abstract available.
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. DiNardo CD, et al. Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25. Blood. 2019. PMID: 30361262 Free PMC article.
Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression.
Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM. Seelan RS, et al. Drug Metab Rev. 2018 May;50(2):193-207. doi: 10.1080/03602532.2018.1437446. Epub 2018 Feb 18. Drug Metab Rev. 2018. PMID: 29455551 Review.
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ. Welch JS, et al. N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949. N Engl J Med. 2016. PMID: 27959731 Free PMC article. Clinical Trial.
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Goldberg JD, Hoffman R. Rampal RK, et al. Blood Adv. 2018 Dec 26;2(24):3572-3580. doi: 10.1182/bloodadvances.2018019661. Blood Adv. 2018. PMID: 30563881 Free PMC article. Clinical Trial.
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A. Santini V, et al. Leukemia. 2018 Feb;32(2):413-418. doi: 10.1038/leu.2017.186. Epub 2017 Jun 13. Leukemia. 2018. PMID: 28607470 Free PMC article. Clinical Trial.
[Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
Zhao XL, Jiang EL, Zhai WH, Ma QL, Pang AM, Wei JL, He Y, Yang DL, Feng SZ, Han MZ. Zhao XL, et al. Zhonghua Xue Ye Xue Za Zhi. 2019 Jun 14;40(6):467-471. doi: 10.3760/cma.j.issn.0253-2727.2019.06.004. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31340618 Chinese.
3,304 results
Jump to page
Feedback